Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

2019 update to Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. White coat hypertension in early pregnancy in women with pre-existing diabetes: prevalence and pregnancy outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • John B Buse
  • Deborah J Wexler
  • Apostolos Tsapas
  • Peter Rossing
  • Geltrude Mingrone
  • Chantal Mathieu
  • David A D'Alessio
  • Melanie J Davies
Vis graf over relationer

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min-1 [1.73 m]-2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.

OriginalsprogEngelsk
TidsskriftDiabetologia
Vol/bind63
Sider (fra-til)221-228
ISSN0012-186X
DOI
StatusUdgivet - jan. 2020

ID: 58665478